JP2011514149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011514149A5 JP2011514149A5 JP2010545219A JP2010545219A JP2011514149A5 JP 2011514149 A5 JP2011514149 A5 JP 2011514149A5 JP 2010545219 A JP2010545219 A JP 2010545219A JP 2010545219 A JP2010545219 A JP 2010545219A JP 2011514149 A5 JP2011514149 A5 JP 2011514149A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- polypeptide
- loop
- polypeptide according
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 118
- 229920001184 polypeptide Polymers 0.000 claims description 114
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 114
- 235000001014 amino acid Nutrition 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 45
- 239000000427 antigen Substances 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 36
- 238000006467 substitution reaction Methods 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 28
- 108060003951 Immunoglobulin Proteins 0.000 claims description 23
- 102000018358 immunoglobulin Human genes 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 230000035772 mutation Effects 0.000 claims description 17
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 102000000989 Complement System Proteins Human genes 0.000 claims description 4
- 108010069112 Complement System Proteins Proteins 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6324508P | 2008-01-31 | 2008-01-31 | |
| US61/063,245 | 2008-01-31 | ||
| PCT/US2009/032692 WO2009099961A2 (en) | 2008-01-31 | 2009-01-30 | Engineered antibody constant domain molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014112059A Division JP2014155503A (ja) | 2008-01-31 | 2014-05-30 | 改変された抗体定常ドメイン分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011514149A JP2011514149A (ja) | 2011-05-06 |
| JP2011514149A5 true JP2011514149A5 (enExample) | 2012-01-26 |
| JP5889533B2 JP5889533B2 (ja) | 2016-03-22 |
Family
ID=40613065
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010545219A Active JP5889533B2 (ja) | 2008-01-31 | 2009-01-30 | 改変された抗体定常ドメイン分子 |
| JP2014112059A Pending JP2014155503A (ja) | 2008-01-31 | 2014-05-30 | 改変された抗体定常ドメイン分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014112059A Pending JP2014155503A (ja) | 2008-01-31 | 2014-05-30 | 改変された抗体定常ドメイン分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8580927B2 (enExample) |
| EP (2) | EP2250196B1 (enExample) |
| JP (2) | JP5889533B2 (enExample) |
| CN (2) | CN101977932B (enExample) |
| AU (1) | AU2009212747B2 (enExample) |
| CA (2) | CA3052615A1 (enExample) |
| WO (1) | WO2009099961A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE414718T1 (de) | 2005-01-05 | 2008-12-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| HUE066143T2 (hu) | 2007-06-26 | 2024-07-28 | F Star Therapeutics Ltd | Kötõágensek megjelenítése |
| WO2009089295A2 (en) * | 2008-01-07 | 2009-07-16 | Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Anti-hiv domain antibodies and method of making and using same |
| CA3052615A1 (en) * | 2008-01-31 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| US20110201785A1 (en) * | 2008-06-30 | 2011-08-18 | Boehringer Ingelheim International Gmbh | Method for optimizing proteins having the folding pattern of immunoglobulin |
| WO2011003811A1 (en) * | 2009-07-09 | 2011-01-13 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilized immunoglobulin constant domains |
| BR112012010252A2 (pt) * | 2009-10-29 | 2016-12-06 | Janssen Biotech Inc | variantes de glicosilação de anticorpo |
| AU2011215684A1 (en) * | 2010-02-12 | 2012-08-30 | Research Corporation Technologies | Multimeric proteins comprising immunoglobulin constant domains |
| WO2012054679A1 (en) * | 2010-10-20 | 2012-04-26 | Medimmune, Llc | Methods for processing inclusion bodies |
| CA2827007A1 (en) * | 2011-02-11 | 2012-08-16 | Research Corporation Technologies, Inc. | Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds |
| CN109517059B (zh) | 2011-06-30 | 2023-03-28 | 中外制药株式会社 | 异源二聚化多肽 |
| US9688731B2 (en) * | 2011-12-22 | 2017-06-27 | Wisconsin Alumni Research Foundation | Isolation and application of BAD-1 for diagnosing infections with Blastomyces dermatitidis |
| CA2863944A1 (en) | 2012-02-10 | 2013-08-15 | Research Corporation Technologies, Inc. | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds |
| US9676857B2 (en) | 2012-03-16 | 2017-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble engineered monomeric Fc |
| EP2855520B1 (en) * | 2012-06-04 | 2018-09-26 | Novartis AG | Site-specific labeling methods and molecules produced thereby |
| US11142563B2 (en) * | 2012-06-14 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified Fc region |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| JP6144487B2 (ja) | 2012-12-26 | 2017-06-07 | 三菱航空機株式会社 | フラップの展開装置、及び、航空機 |
| CN105940107B (zh) | 2013-11-11 | 2021-06-15 | 中外制药株式会社 | 含有改变了抗体可变区的抗原结合分子 |
| EP3209329A4 (en) * | 2014-10-24 | 2018-03-28 | Research Corporation Technologies, Inc. | Small antibody-like polypeptides that bind to epha2 receptor |
| WO2016076345A1 (ja) | 2014-11-11 | 2016-05-19 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子のライブラリ |
| JP6872797B2 (ja) * | 2015-12-29 | 2021-05-19 | 国立大学法人東京工業大学 | 標的結合ペプチドの安定化方法 |
| CN109641949B (zh) * | 2016-08-26 | 2023-09-15 | 赛诺菲 | 促进选择性轻链配对的多特异性抗体 |
| ES2880010T3 (es) * | 2017-01-09 | 2021-11-23 | Lentigen Tech Inc | Composiciones y métodos para tratar el cáncer con inmunoterapia antimesotelina |
| SI3583120T1 (sl) | 2017-02-17 | 2023-02-28 | Denali Therapeutics Inc. | Inženirani polipeptidi, ki vezujejo transferinske receptorje |
| AU2018240029A1 (en) | 2017-03-22 | 2019-10-17 | Research Corporation Technologies, Inc. | Engineered stable CH2 polypeptides |
| WO2018193063A2 (en) | 2017-04-19 | 2018-10-25 | Institute For Research In Biomedicine | Novel malaria vaccines and antibodies binding to plasmodium sporozoites |
| JP7357616B2 (ja) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Ｃｄ３およびｃｄ１３７に結合する改変された抗体可変領域を含む抗原結合分子 |
| JP7489316B2 (ja) * | 2017-12-19 | 2024-05-23 | エフ－スター セラピューティクス リミテッド | Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片 |
| CN108191974B (zh) * | 2017-12-31 | 2021-04-09 | 武汉班科生物技术股份有限公司 | 抗聚集人源IgG抗体CH2结构域突变体及应用 |
| WO2021062012A1 (en) | 2019-09-25 | 2021-04-01 | Emory University | Use of klk10 and engineered derivatizations thereof |
| CA3173587A1 (en) | 2020-03-31 | 2021-10-07 | Chugai Seiyaku Kabushiki-Kaisha | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
| WO2022067020A1 (en) * | 2020-09-24 | 2022-03-31 | The Broad Institute, Inc. | Cell-free antibody engineering platform and neutralizing antibodies for sars-cov-2 |
| WO2023087017A1 (en) * | 2021-11-15 | 2023-05-19 | Alector Llc | Proteins comprising blood brain barrier (bbb)-binding domains within constant domains |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
| US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
| US5208021A (en) | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
| US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5965709A (en) * | 1991-08-14 | 1999-10-12 | Genentech, Inc. | IgE antagonists |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US7264963B1 (en) | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
| EP3321282A1 (en) | 2002-09-27 | 2018-05-16 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| ITRM20020588A1 (it) | 2002-11-21 | 2004-05-22 | Lay Line Genomics Spa | Metodo per isolare anticorpi intracellulari neutralizzanti di interazioni proteiche. |
| CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
| DK1797127T3 (en) * | 2004-09-24 | 2017-10-02 | Amgen Inc | Modified Fc molecules |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| ATE414718T1 (de) | 2005-01-05 | 2008-12-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| EP1877441A2 (en) * | 2005-04-26 | 2008-01-16 | Bioren, Inc. | Method of producing human igg antibodies with enhanced effector functions |
| EP1931709B1 (en) * | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| JP2009526750A (ja) * | 2005-12-22 | 2009-07-23 | セントカー・インコーポレーテツド | Ｇｌｐ−１アゴニスト、組成物、方法および使用 |
| AT503889B1 (de) * | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
| EP2738257A1 (en) * | 2007-05-22 | 2014-06-04 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| CA3052615A1 (en) * | 2008-01-31 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
| AU2011215684A1 (en) | 2010-02-12 | 2012-08-30 | Research Corporation Technologies | Multimeric proteins comprising immunoglobulin constant domains |
| CA2827007A1 (en) * | 2011-02-11 | 2012-08-16 | Research Corporation Technologies, Inc. | Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds |
-
2009
- 2009-01-30 CA CA3052615A patent/CA3052615A1/en not_active Abandoned
- 2009-01-30 EP EP09709399A patent/EP2250196B1/en active Active
- 2009-01-30 CA CA2713281A patent/CA2713281C/en active Active
- 2009-01-30 EP EP12198382.9A patent/EP2594584B1/en active Active
- 2009-01-30 JP JP2010545219A patent/JP5889533B2/ja active Active
- 2009-01-30 AU AU2009212747A patent/AU2009212747B2/en active Active
- 2009-01-30 CN CN200980110221.1A patent/CN101977932B/zh active Active
- 2009-01-30 WO PCT/US2009/032692 patent/WO2009099961A2/en not_active Ceased
- 2009-01-30 US US12/864,758 patent/US8580927B2/en active Active
- 2009-01-30 CN CN201410422052.8A patent/CN104250301A/zh active Pending
-
2013
- 2013-10-01 US US14/043,366 patent/US9527903B2/en active Active
-
2014
- 2014-05-30 JP JP2014112059A patent/JP2014155503A/ja active Pending
-
2016
- 2016-12-02 US US15/367,488 patent/US10358481B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011514149A5 (enExample) | ||
| JP2021020905A5 (enExample) | ||
| JP6839101B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| TWI713942B (zh) | 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類 | |
| KR101522954B1 (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
| JP2025011161A (ja) | プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用 | |
| JP7496091B2 (ja) | 合理的に設計された新規なタンパク質組成物 | |
| JP6473418B2 (ja) | 抗ポドプラニン抗体 | |
| JP2011526480A5 (enExample) | ||
| JP2020186248A5 (enExample) | ||
| JP7486810B2 (ja) | ＩｇＧ１ Ｆｃモノマー、及びその使用 | |
| AU783148B2 (en) | Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| Golay et al. | Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies | |
| JP2018510147A (ja) | Ｃｄ４７に結合する抗体医薬 | |
| JP2013529070A5 (enExample) | ||
| JP2014521313A5 (enExample) | ||
| JP2020505919A5 (enExample) | ||
| JP2012532838A (ja) | 安定化された免疫グロブリン定常ドメイン | |
| JP2015520172A5 (enExample) | ||
| CN113968910A (zh) | 四价对称双特异性抗体 | |
| JPWO2019204564A5 (enExample) | ||
| IL301473A (en) | EGFR binding complex and how it is created and used | |
| EP4069298A1 (en) | Composition of triaxial antibodies and method of making and using thereof | |
| JP2008507253A5 (enExample) |